Key Highlights

  • Karyopharm Therapeutics (NASDAQ:KPTI) lost 34.75% to USD 0.0261 following a Chapter 11 filing on November 2, 2026, with Nasdaq trading halted from the open on November 11.
  • CDT Equity (NASDAQ:CDT) lost 23.52% to USD 0.6425 in the third session after a 1-for-20 reverse split, with a Market Value of USD 653.98 thousand.
  • Evolution Metals & Technologies (NASDAQ:EMAT) lost 37.84% to USD 1.36 after a lender said it did not pay USD 34,672,219.18 owed on two debentures.
  • Trading ranged from 348.86K shares at a relative Volume of 0.07 for CDT Equity to 4.59 million shares at 0.14 for Karyopharm, and 1.1 million shares at 1.46 for Evolution Metals.

Karyopharm Therapeutics (NASDAQ:KPTI): Down 34.75% on Chapter 11 and a Nasdaq Delisting Notice

Karyopharm Therapeutics (NASDAQ:KPTI) closed the regular session on Tuesday, November 10, 2026 at USD 0.0261, a fall of 34.75% from a calculated prior close of USD 0.0400. The catalyst is the Bankruptcy process, not a fresh Tuesday announcement. Karyopharm and its Subsidiary KPT Texas LLC filed Chapter 11 petitions in the Southern District of Texas on November 2, 2026 with a prepackaged plan. An 8-K signed November 5 said Nasdaq delivered a delisting notice on November 4, the company will not appeal, trading halts at the open on November 11, and common and Series A preferred holders are due no distribution. OTC quotes are expected under KPTIQ. Earlier coverage put the Loan at USD 55 million and named Ayrmid as lead bidder. In pre-market trading that morning the stock was indicated near USD 0.0311, down 22.25%, so the loss deepened during the session. As general context, forced selling by funds that cannot hold Delisted names often pressures such stocks, which is not a confirmed cause of Tuesday's drop. Trading was 4.59 million shares at a relative volume of 0.14, worth about USD 0.12 million (calculated). The USD 591.99 thousand market value implies about 22.68 million shares (calculated), against earlier published total Debt near USD 328.53 million, so equity is a tiny slice of the capital structure. Trailing diluted EPS is USD -13.08 and no P/E exists. One tick lower on a USD 0.0261 quote is about 3.8% (calculated). Volume ran about 86% under the recent average, so a few trades can move the price, and the chief risk is a total loss for common holders. Nothing here suggests the move will continue.

CDT Equity (NASDAQ:CDT): Down 23.52% on a 1-for-20 Reverse Stock Split

CDT Equity (NASDAQ:CDT) closed Tuesday at USD 0.6425, a fall of 23.52% from a calculated prior close of USD 0.84, the third split-adjusted session after November 6 and November 9. The catalyst is the 1-for-20 reverse split. The 8-K signed November 4 said a certificate of amendment was filed in Delaware on November 2, the split took effect at 5:00 p.m. ET on November 5, and split-adjusted shares began trading on November 6, shrinking shares outstanding from 20,357,283 to about 1,017,864. No fractional shares were issued. As general context, a split multiplies the quoted price by 20 without altering the value of a holding, and trading afterwards is often choppy, which is not a confirmed cause of this drop. Published coverage showed no results or guidance dated November 9 or 10. The market value of USD 653.98 thousand reconciles with about 1,017,864 shares at USD 0.6425 (calculated). Trading of 348.86K shares, a relative volume of 0.07, equals about 34.3% of shares outstanding (calculated), a thin float in which a few trades can move the price. The EPS print of USD -2,834,501.10 looks like a display artifact, and 2026 filings include an S-1 and a 424B3, which point to dilution. At USD 0.6425 the stock sits about 35.8% under USD 1.00 (calculated). Nothing here suggests the move will continue. On the old basis, USD 0.6425 is about USD 0.032 per pre-split share (calculated), and a relative volume of 0.07 implies an average near 4.98 million shares that blends pre-split volume, so the comparison is unreliable. The ticker stays CDT on the Nasdaq Capital Market, and redeemable warrants trade as CDTTW.

Evolution Metals & Technologies (NASDAQ:EMAT): Down 37.84% on a Reported Debenture Default

Evolution Metals & Technologies (NASDAQ:EMAT), a rare earth and critical minerals company, finished at USD 1.36, a fall of 37.84% from a calculated prior close of USD 2.19. The catalyst is a November 9, 2026 release at 4:09 p.m. ET from lender YA II PN, a Yorkville fund. It said the company owed USD 34,672,219.18 including 5% payment premiums and accrued interest on two debentures, USD 10.9 million of remaining principal from May 7, 2026 and USD 22.0 million from September 17. A five-trading-day cure period lapsed on November 5 without payment, the Event of Default raises the Interest Rate to 18% a year, and the company pulled a proposed underwritten offering. Yorkville said the chief financial officer sent a draft Form S-1 and requested an extension to November 27, 2026. Yorkville also said it may accelerate the debt, convert it into common stock and sell shares. This is the lender's account, and the company's reply was not in the material reviewed. Trading was 1.1 million shares at a relative volume of 1.46, about USD 1.50 million (calculated). The snapshot market value of USD 849.86 million implies about 625 million shares (calculated) and is unconfirmed. Trailing EPS is USD -1.01 with EPS growth of -90.71%. Dilution, share sales by the lender, acceleration of the USD 34.7 million claim and the loss of a funding route are the specific risks. The release did not disclose the company's cash balance. The 18% default rate adds pressure to a company already posting widening losses, and nothing suggests the move will continue.

Where Things Stand

The most severe distress story among market movers on November 10, 2026 was Evolution Metals & Technologies (NASDAQ:EMAT), down 37.84%. Karyopharm Therapeutics (NASDAQ:KPTI) followed at -34.75%. CDT Equity (NASDAQ:CDT) lost 23.52%. The shared feature is a Balance Sheet or Capital Structure event: a missed debt payment, a Chapter 11 filing and a reverse split. Large one-day moves in thinly traded names can reverse the next session because a few orders set the price and filings can reset expectations. These lists rest on a published screener snapshot of the regular session on November 10, 2026.